A Study of Lebrikizumab in Patients with Chronic Obstructive Pulmonary Disease

Update Il y a 5 ans
Reference: EUCTR2015-001122-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

• To evaluate the efficacy of lebrikizumab compared with placebo in improving lung function, as measured by the absolute change in pre-bronchodilator forced expiratory volume in one second (FEV1) in patients with COPD and a history of exacerbations in the biomarker-high group (elevated serum periostin and blood eosinophils) and biomarker low group.


Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)